ES2011120A6 - Forma de dosificacion para tratar las enfermedades cardiovasculares. - Google Patents

Forma de dosificacion para tratar las enfermedades cardiovasculares.

Info

Publication number
ES2011120A6
ES2011120A6 ES8802980A ES8802980A ES2011120A6 ES 2011120 A6 ES2011120 A6 ES 2011120A6 ES 8802980 A ES8802980 A ES 8802980A ES 8802980 A ES8802980 A ES 8802980A ES 2011120 A6 ES2011120 A6 ES 2011120A6
Authority
ES
Spain
Prior art keywords
isradipine
dosage form
cardiovascular diseases
treating cardiovascular
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES8802980A
Other languages
English (en)
Inventor
Atul Davdatt Ayer
David R Swanson
Anthony L Kuczynsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of ES2011120A6 publication Critical patent/ES2011120A6/es
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

FORMA DE DOSIFICACION PARA TRATAR LAS ENFERMEDADES CARDIOVASCULARES. ESTA INVENCION DESCRIBE UN DISPOSITIVO OSMOTICO QUE INCLUYE UNA PRIMERA COMPOSICION Y UNA SEGUNDA COMPOSICION QUE CONTIENE EL BENEFICIOSO FARMACO ISRADIPINA EN LA PRIMERA COMPOSICION, QUE ES UTIL EN EL TRATAMIENTO DE LAS ENFERMEDADES CARDIOVASCULARES.
ES8802980A 1987-10-02 1988-09-30 Forma de dosificacion para tratar las enfermedades cardiovasculares. Expired ES2011120A6 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/104,006 US4816263A (en) 1987-10-02 1987-10-02 Dosage form for treating cardiovascular diseases comprising isradipine

Publications (1)

Publication Number Publication Date
ES2011120A6 true ES2011120A6 (es) 1989-12-16

Family

ID=22298196

Family Applications (1)

Application Number Title Priority Date Filing Date
ES8802980A Expired ES2011120A6 (es) 1987-10-02 1988-09-30 Forma de dosificacion para tratar las enfermedades cardiovasculares.

Country Status (22)

Country Link
US (1) US4816263A (es)
JP (1) JP2590235B2 (es)
KR (1) KR950010151B1 (es)
AT (1) AT402689B (es)
AU (1) AU615215B2 (es)
BE (1) BE1001101A5 (es)
CA (1) CA1317550C (es)
CH (1) CH677609A5 (es)
DE (1) DE3833282C2 (es)
DK (1) DK175564B1 (es)
ES (1) ES2011120A6 (es)
FI (1) FI92554C (es)
FR (1) FR2622798B1 (es)
GB (1) GB2210266B (es)
IE (1) IE61862B1 (es)
IT (1) IT1234215B (es)
LU (1) LU87351A1 (es)
NL (1) NL194748C (es)
NO (1) NO176466C (es)
PT (1) PT88618B (es)
SE (1) SE503471C2 (es)
ZA (1) ZA887362B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816263A (en) * 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
US4946687A (en) * 1987-10-02 1990-08-07 Alza Corporation Dosage form for treating cardiovascular diseases
US5208037A (en) * 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
US5674895A (en) * 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US6124355A (en) * 1995-05-22 2000-09-26 Guittard; George V. Oxybutynin therapy
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US20040062799A1 (en) * 1997-09-29 2004-04-01 Ayer Atul D. Therapeutic composition and delivery system for administering drug
DE19747261A1 (de) * 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
AR018321A1 (es) * 1998-03-26 2001-11-14 Alza Corp Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
US20010038855A1 (en) * 1998-06-05 2001-11-08 Desjardin Michael A. Dosage form for administering prescribed dose
US6238697B1 (en) 1998-12-21 2001-05-29 Pharmalogix, Inc. Methods and formulations for making bupropion hydrochloride tablets using direct compression
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
AU2002345664C1 (en) * 2001-06-11 2008-03-06 Xenoport, Inc. Prodrugs of gaba analogs, compositions and uses thereof
EP1412324A4 (en) * 2001-06-11 2004-09-29 Xenoport Inc AMINO ACID CONJUGATES THAT RESULT IN GABA ANALOGA LASTING SYSTEMIC CONCENTRATIONS
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6524618B1 (en) 2001-06-12 2003-02-25 Vijai Kumar Directly compressible extended-release matrix formulation for metformin hydrochloride
WO2004052841A1 (en) 2002-12-06 2004-06-24 Xenoport, Inc. Carbidopa prodrugs and uses thereof
US20040162351A1 (en) * 2002-12-11 2004-08-19 Gallop Mark A. Orally administered dosage forms of fused GABA analog prodrugs having reduced toxicity
WO2004089289A2 (en) * 2003-03-31 2004-10-21 Xenoport, Inc. Treating or preventing hot flashes using prodrugs of gaba analogs
EP2354120A1 (en) 2003-08-20 2011-08-10 XenoPort, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
US7109239B2 (en) * 2003-08-20 2006-09-19 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
CA2537837A1 (en) * 2003-09-11 2005-03-24 Xenoport, Inc. Treating and/or preventing urinary incontinence using prodrugs of gaba analogs
WO2005027850A2 (en) * 2003-09-17 2005-03-31 Xenoport, Inc. Treating or preventing restless legs syndrome using prodrugs of gaba analogs
US20060128676A1 (en) * 2004-07-13 2006-06-15 Pharmacofore, Inc. Compositions of nicotinic agonists and therapeutic agents and methods for treating or preventing diseases or pain
WO2006050471A2 (en) * 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
US7494985B2 (en) * 2004-11-03 2009-02-24 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use
WO2006050514A1 (en) 2004-11-04 2006-05-11 Xenoport, Inc. Gabapentin prodrug sustained release oral dosage forms
WO2007002013A2 (en) 2005-06-20 2007-01-04 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use
EP1896002A4 (en) 2005-06-27 2009-11-25 Biovail Lab Int Srl BUPROPIONAL SALT FORMULATIONS WITH MODIFIED RELEASE
US20070049626A1 (en) * 2005-08-26 2007-03-01 Tran Pierre V Treating premature ejaculation using gabapentin and pregabalin prodrugs
US20070128282A1 (en) * 2005-12-02 2007-06-07 Patel Hasmukh B Oral osmotic drug delivery system
EP2402037B8 (en) 2006-05-26 2019-12-04 Signature Therapeutics, Inc. Controlled release of phenolic opioids
US7585996B2 (en) * 2006-09-15 2009-09-08 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
CN101652133A (zh) * 2006-12-08 2010-02-17 克塞诺波特公司 Gaba类似物的前药用于治疗疾病的用途
US7714201B2 (en) * 2006-12-22 2010-05-11 Monsanto Technology Llc Cotton variety 781000G
US7419684B2 (en) * 2006-12-22 2008-09-02 Reliant Pharmaceuticals, Inc. System and method for manufacturing oral osmotic drug delivery devices, and methods of administering same
WO2008124121A1 (en) * 2007-04-06 2008-10-16 Scidose, Llc Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters
WO2011028234A1 (en) * 2009-09-04 2011-03-10 Xenoport, Inc. Uses of acyloxyalkyl carbamate prodrugs of tranexamic acid
DK2621282T3 (da) 2010-09-28 2020-05-04 Univ California Gaba-agonister i behandlingen af forstyrrelser forbundet med metabolisk syndrom og gaba-kombinationer i behandling eller profylakse af type i diabetes
CN102349880B (zh) * 2011-10-12 2015-07-22 合肥华方医药科技有限公司 伊拉地平控释片及其制备方法
CN105030726A (zh) * 2015-08-30 2015-11-11 四川百利药业有限责任公司 一种伊拉地平胶囊的制备方法
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
GB2556817B (en) 2015-10-01 2019-11-06 Elysium Therapeutics Inc Polysubunit opioid prodrugs resistant to overdose and abuse
CA3056239C (en) 2017-03-17 2023-09-12 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
CH639659A5 (de) * 1978-12-18 1983-11-30 Sandoz Ag Neue 1,4-dihydropyridinderivate, deren herstellung und verwendung.
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
NZ206600A (en) * 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
HU198844B (en) * 1984-06-14 1989-12-28 Sandoz Ag Process for producing new galenic pharmaceutical composition ensuring retarded release of active ingredient
US4627851A (en) * 1984-10-26 1986-12-09 Alza Corporation Colonic-therapeutic delivery system
US4624847A (en) * 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
GB2181053B (en) * 1985-10-01 1990-05-23 Sandoz Ltd Pharmaceutical formulations with controlled release of the active substance
US4723957A (en) * 1986-02-07 1988-02-09 Alza Corp. System for delivering drug with enhanced bioacceptability
US4753802A (en) * 1986-03-19 1988-06-28 Alza Corporation Verapamil dosage form
AU2152888A (en) * 1987-08-25 1989-03-02 Cerra Metal Works Pty. Ltd. Masonry tie
US4816263A (en) * 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine

Also Published As

Publication number Publication date
AT402689B (de) 1997-07-25
IE882960L (en) 1989-04-02
FI884526A0 (fi) 1988-09-30
SE8803486L (sv) 1989-04-03
CH677609A5 (es) 1991-06-14
IE61862B1 (en) 1994-11-30
FR2622798B1 (fr) 1993-10-15
NO884259D0 (no) 1988-09-27
PT88618A (pt) 1989-07-31
DK545088D0 (da) 1988-09-29
SE8803486D0 (sv) 1988-09-30
FI92554C (fi) 1994-12-12
DE3833282C2 (de) 1997-02-13
NL194748B (nl) 2002-10-01
FR2622798A1 (fr) 1989-05-12
NO176466B (no) 1995-01-02
LU87351A1 (fr) 1989-04-06
AU2293888A (en) 1989-04-06
FI884526A (fi) 1989-04-03
CA1317550C (en) 1993-05-11
BE1001101A5 (fr) 1989-07-11
GB2210266A (en) 1989-06-07
GB8822852D0 (en) 1988-11-02
SE503471C2 (sv) 1996-06-24
DE3833282A1 (de) 1989-04-20
NO176466C (no) 1995-04-12
AU615215B2 (en) 1991-09-26
KR950010151B1 (ko) 1995-09-11
NL8802401A (nl) 1989-05-01
US4816263A (en) 1989-03-28
ZA887362B (en) 1989-06-28
DK545088A (da) 1989-04-03
IT8867880A0 (it) 1988-09-30
KR890006218A (ko) 1989-06-12
JP2590235B2 (ja) 1997-03-12
IT1234215B (it) 1992-05-06
FI92554B (fi) 1994-08-31
GB2210266B (en) 1991-07-24
NO884259L (no) 1989-04-03
DK175564B1 (da) 2004-12-06
ATA242288A (de) 1996-12-15
NL194748C (nl) 2003-02-04
JPH01113316A (ja) 1989-05-02
PT88618B (pt) 1993-07-30

Similar Documents

Publication Publication Date Title
ES2011120A6 (es) Forma de dosificacion para tratar las enfermedades cardiovasculares.
DE3760201D1 (en) (-)-benzhydrylsulfinylacetamide, process for its preparation and its use in therapy
AU587307B2 (en) Verapamil dosage form
CA2001618A1 (en) Gestodene-containing agent for transdermal administration
GB8820460D0 (en) Dosage form comprising fast agent delivery followed by slow agent delivery
IL91706A (en) Pharmaceutical compositions comprising in separate dosage form a plasminogen activator and hirudin
AU8093487A (en) Improvement in bromphenriamine, pseudoephedrine therapy
IE882391L (en) Pad printing process
IL87089A0 (en) N-aminobutyl-n-phenylarylamide derivatives,their preparation and their application in therapy
AU6788687A (en) A pharmaceutical which can be administered nasally, a process for its preparation, and its use
AU1375888A (en) Anti-viral compounds, dosage forms and methods
ES8403884A1 (es) Un procedimiento para la preparacion de nuevos 2,3-diaril-5-halotiofenos.
EP0106341A3 (en) Physiologically active substance p-23924, its production and use
ZA872128B (en) Chlorpheniramine therapy
SE8204871L (sv) Farmaceutiska preparat, innefattande humant proinsulin
AU2192783A (en) 3:,5:-diarabinosides preparation and application in therapy
ZA864717B (en) Terguride as a geriatric agent
GR3015373T3 (en) 2-Halogen-substituted N-indolyl sulfonic-acid amides, process for their preparation and their pharmaceutical use.
DE3460891D1 (en) 2,6-exo configured tricyclo (5.2.1.0(2,6)) decane derivatives with functional side chain in c-8/c-9 and utilization thereof as perfumes
Cook Validation of a growth hormone radioimmunoassay and its application to neuroendocrine studies in the goldfish, Carassius auratus
USD275234S (en) Microbiological testing syringe
GB2213062A (en) Pharmaceutical preparation having oestrogen action
EP0310238A3 (en) New physiologically active substances, probestin and prostatin and production thereof
JPS5216871A (en) Aeration unit
JPS5373554A (en) 2, 10-dehydro-4-homobrendane and its preparation

Legal Events

Date Code Title Description
SA6 Expiration date (snapshot 920101)

Free format text: 2008-09-30

FD1A Patent lapsed

Effective date: 20081001